Clinical Trials Browser

Phase 1/2 × Graft vs Host Disease × Busulfan × Clear all

Graft vs Host Disease, Hematologic Neoplasms

NCT00822770 2020-10-14

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT00679536 2014-01-23

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

Phase 1/2 Unknown

30 enrolled

Other hematologic neoplasm

Graft vs Host Disease, Leukemia

NCT00054340 2010-05-14

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

Phase 1/2 Completed

MyeloidOther hematologic neoplasm

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Clinical Trials

Optimizing PTCy Dose and Timing

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder